INS and metabolic syndrome: However, a much wider use of this drug can be implemented as a viable cardiovascular preventive strategy, starting with the many millions of non-diabetic insulin resistant individuals with metabolic syndrome, until considering even the elderly population with its burden of several comorbidities [228,233], and those suffering from some common rheumatologic diseases closely associated with cardiovascular risk such as rheumatoid arthritis and gout [234].